About the European Association of Systems Medicine
The European Association of Systems Medicine e.V. (EASyM) is a charitable association open to everyone with an interest in personalised medicine and systems medicine. The concept of personalised medicine, or rather P4 medicine (predictive, personalised, preventive, participatory medicine), requires not just the acquisition but also the processing of large amounts of personal data. There are too many factors and interactions playing a role in the progression of complex diseases such as cancer, cardiovascular, inflammatory or metabolic diseases to get any meaningful results out of the raw data. Systems Medicine builds on the integration and analysis of complex data sets through mathematical algorithm and computational modelling. See an example of successful application of Systems Medicine below.
The aim of EASyM is to foster Systems Medicine approaches in experimental medicine and clinical research. EASyM strives to integrate all relevant stakeholders, including clinicians, researchers, medical and patient organisations, industry, funders & policy makers. In particular, EASyM aims to
- Organise annual conferences
- Offer Systems Medicine training courses and provide educational material
- Promote Systems Medicine publications, either through special issues in established journals or establishing a Systems Medicine-dedicated journal
- Provide comprehensive information and databases about Systems Medicine to the public and to all relevant communities & disciplines
- Offer intersectoral and interdisciplinary partnering events
- Organise seminars to discuss interdisciplinary, ethical, societal and economic issues of the implementation of Systems Medicine and the acquisition of personal medical data
- Offer of contacts, advice and infrastructure for the planning, application and implementation of research and educational programs
- Become the voice of Systems Medicine in Europe and for the European Commission
Becoming a member of EASyM
EASyM is open for both personal as well as institutional memberships. Being a member will entail several advantages including access to a Europe-wide network of Systems Medicine experts stakeholders, participation in exclusive networking and training events, regular updates on current advances in the field as well as direct and personal contribution to the development of an inclusive European strategy for Systems Medicine. For further details about EASyM membership, please click here.
EASyM and CASyM
EASyM was initiated as part of the FP7-funded Coordinating Action Systems Medicine (CASyM, www.casym.eu). CASyM defined a first road map for implementing the Systems Biology approach within medical research and practice. CASyM-based activities have revealed a strong interest in Europe across sectors and disciplines in the value of Systems Medicine for European healthcare. EASyM will take on the legacy of CASyM, including the preservation, application and expanding of resources build up by CASyM and will continue CASyM’s long-term vision of establishing systems medicine-based practices in European healthcare.
Founding of EASyM
EASyM was founded on 30th September 2015 in Brussels by 27 medical doctors, researchers and health care stakeholders from 12 different countries. On that date, an Executive Board of 7 members was also elected (details about Executive Board click here). EASyM was officially registered in Aachen, Germany (which borders to both Belgium and the Netherlands) on 18th March 2016. Due to its charitable status, it is exempted from corporate tax. As an independent organisation, it is able to receive sponsorship and donations for the advancement of personalised and systems medicine.
For further information about EASyM, please email firstname.lastname@example.org
An example of systems medicine success is the approval of the drug Ranolazine, a treatment for chronic angina. Ranolazine reduces the late sodium current in cardiac cells but is also a strong blocker of the hERG potassium channel in the human heart. Blockage of hERG can lead to an irregular heart beat and subsequent cardiac arrest, which is why strong hERG blockers usually do not get approval as prescriptive drugs. However, mathematical modelling enabled the understanding of how the reduction of late sodium currents negated the pro-arrhythmic effects of hERG blockage and could turn it into something positive, i.e. alleviating chronic angina. Based on this proof through mathematical modelling, Ranolazine was approved by the FDA.
Mirams GR, Davies MR, Cui Y, Kohl P, Noble D. Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing. Br J Pharmacol 2012, 167:932-945.